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Introduction	  
It has been over 25 years since the “miniaturized total (chemical) analysis system”, or 
MicroTAS, concept was first presented by Andreas Manz at the Transducers’89 conference 
in Montreux, Switzerland. This concept, originating as it does from analytical chemists, is 
based on the idea that multiple sample handling steps could be integrated into 
interconnected microfluidic channel networks as the basis for “sample-in, answer-out” 
analytical devices. The MicroTAS thus embodies a strategy for automation of 
(bio)chemical processing, involving flow systems for sample transport, handling and 
analysis. The performance of these systems is enhanced by virtue of the fact that the 
solution volumes involved are small, from a few microliters down to amounts measurable 
in attoliters. The small dimensions of the MicroTAS are its main strength, as solution flows 
at this scale are well-defined and can be controlled with exquisite precision. It is not 
surprising, then, that the MicroTAS has evolved into microfluidics, the science and 
technology of systems for processing fluids in microchannels [1], and the more 
applications-oriented concept, lab-on-a-chip. Microfluidics technology offers researchers 
an unparalleled opportunity to create and control flow and force gradients in 
microenvironments. This unique ability can be further exploited to exercise dynamic 
   
 
control over the (bio)chemical environment in the confined space of a microfluidic channel 
by directed transport and generation of gradients on a molecular level.  Though invented by 
analytical chemists, the potential of microfluidics has therefore been recognized and 
embraced by researchers in quite different fields for a host of applications other than 
analytical chemistry.  
The MicroTAS has been successfully repurposed over the past twenty years or so for 
engineering cellular microenvironments which more faithfully mimic in vivo conditions for 
cell- and tissue-based studies. Organs-on-a-chip are a recent outgrowth of this effort, 
comprising systems that extend beyond microfluidic perfusion culture to include the 
possibility to recreate tissue structure, as well as intratissue transport and mechanical 
function. Successful examples have included devices for a “breathing” lung [2,3] and a 
“peristaltic” intestine [4]. With the ability to make better biomimetic organ-chips comes the 
desire, indeed necessity, to monitor cell growth and characterize cell behaviour under 
controlled conditions. Qualitative information about a culture can be obtained from cell 
appearance or tissue morphology. However, this information is often limited, and is better 
correlated with quantitative data for parameters such as pH, dissolved oxygen, nutrient 
consumption, release of biomarkers for viability and relevant metabolites to obtain a more 
complete picture of cell behavior. The possibility to integrate analytical functionality into 
organ-chips is now being exploited to actively control conditions in these biological 
systems. A major challenge for the analytical chemist has become how to probe miniscule 
culture volumes directly, with temporal and spatial resolution, using previously developed 
or newly invented microanalytical or lab-on-a-chip approaches.  
This presentation will focus in part on our development of a microfluidic incubation system 
for drug metabolism studies using a “top-down” precision-cut tissue slice model. We have 
been able to leverage microfluidics to perform experiments which would not have been 
possible in a wellplate, including the demonstration of intestine-liver interaction ex vivo. 
The second part of the presentation will describe a more fundamental particle separation 
concept which relies on the generation of controlled bi-directional flow in microchannels 
having variable cross-sectional dimensions, by opposing pressure-driven and electrokinetic 
flows. While these two applications may seem quite disparate, they both represent a unique 
ability to perform experiments under flow with a degree of precision which would 
otherwise not have been possible without microfluidics. Moreover, continuing to improve 
our basic understanding of how to manipulate and control fluid, particle and molecular 
transport in confined microchannels is essential for fueling future microfluidic innovation 
in chemistry and the life sciences. 
A	  	  microfluidic	  	  multi-­‐organ	  	  platform	  	  for	  	  drug	  	  testing	  	  and	  	  
understanding	  	  disease	  
Early information on the metabolism and toxicity properties of new drug candidates is 
crucial for selecting the right candidates for further development. Preclinical studies rely on 
mammalian and human cell-based in vitro tests and animal studies to predict the in vivo 
behaviour of drug candidates in man, though neither are ideal predictors of drug behaviour 
in humans. While animal species sometimes share some similarity with humans with 
respect to drug metabolism, species differences remain unpredictable and substantial 
enough to make extrapolation of animal-derived data (both in vivo and in vitro) to humans 
often difficult. In vitro tests with cells of human origin, on the other hand, suffer from a 
different drawback, namely that cell monocultures lack the tissue structure and, 
   
 
importantly, proper expression of endogenous enzymes and transporters which dictate drug 
exposure and metabolism in vivo. Improving in vitro systems for preclinical studies thus 
remains a major challenge, motivated both by a desire to reduce the use of animals for 
practical and ethical reasons and improve the quality of data obtained with human cells. 
Microfluidics can be exploited to come closer to this goal, in combination with precision-
cut liver slices (PCLS) as an improved, “top-down” organotypic system.  
A major advantage of PCLS over hepatocytes or cell lines for in vitro studies on liver 
function is that all the different cell types are present in their natural tissue-matrix 
configuration. Clearly, however, human tissue is not readily available, and it is worthwhile 
considering how to perform a maximum number of informative experiments with small 
amounts of material. 
We developed a novel microfluidic-based (biochip) system to perform metabolism and 
toxicity studies with mammalian PCLS under continuous flow (see Figure 1) [5,6]. A 
biochip was designed to integrate slices of liver in small, sequentially connected 
microchambers (25 µL) that can be continuously perfused. The requirements for this low-
cost microfluidic device were biocompatibility, and the maintenance of constant oxygen 
concentration, pH, medium composition and temperature conditions over time. The 
resulting poly(dimethylsiloxane) (PDMS) flow-through microdevice integrated 
polycarbonate membranes to realize a well-defined medium flow, and integrated PDMS 
membranes to act as “breathing” membranes for oxygen supply. Perifusion of the slices 
suspended in solution (medium flowed around the slices) in the microchamber ensured a 
continuous influx of nutrients and oxygen and a continuous removal of waste products.  
Studies with mammalian slices have shown that the use of microfluidics makes more 
sophisticated experimentation possible when compared to conventional well-plate formats. 
For example, it was possible to couple the outlets of three different microchambers 
containing perifused liver slices to a series of three HPLC injectors for automated, 
sequential on-line monitoring of metabolites. Because of the low volumes and flowrates 
Figure 1: (Left) Top view of a 10-layer poly(dimethylsiloxane) device with three 25-µL chambers, 
each containing a liver slice ( 4 mm diameter, 100-250 µm thick. The slices are suspended in 
medium flowing from the bottom of the device and exiting through the top. (Right) Biochip 
configuration for organ interaction experiment. An intestinal slice (rat) is located in the right 
chamber, the outlet of which is connected to the inlet of the second chamber containing a liver 
slice (also rat). The organs are represented figuratively. 
 
   
 
involved, relatively high concentrations of metabolites could be achieved, enabling 
sensitive detection [7]. The biochip also enables the in vitro measurement of interorgan 
effects, by connecting the outlet of one chamber to the inlet of another chamber containing 
a slice from a different organ (Figure 1) [8]. The outlet of a microchamber containing a rat 
intestinal slice was coupled to the inlet of a microchamber containing a rat liver slice. The 
interplay between intestinal and liver slices was then assessed by introducing medium 
containing the primary bile acid, chenodeoxycholic acid. Upon exposure to this bile acid, 
the intestinal slice produced a protein, growth factor FGF15, which caused a down-
regulation of the enzyme, cytochrome P450 7A1, responsible for bile acid synthesis in the 
liver, as known for the rat in vivo. By using our biochip system, we were able to show this 
organ interaction with in vitro testing. In vivo testing with animals is possible; however, in 
vivo testing of such organ interactions in humans is virtually impossible. The incorporation 
of human material in our device could bring the study of such human organ interactions in 
vitro closer to reality.   
Two-­‐dimensional	  	  orthogonal	  	  particle	  	  separations	  	  in	  	  nanoliter	  	  flows	  
As the range of applications for lab-chip technologies broadens, integrated methods for 
manipulating, sorting and separating particles in microfluidic systems become ever more 
relevant. Approaches based on laminar flows and applied electric fields are popular as they 
are easy to implement, provided careful thought has been given to microchannel geometry 
and layout. We have combined hydrodynamic and electrokinetic effects in a microchannel 
to preconcentrate and separate particles based on differences in their charge (zeta potential) 
[9]. This was done by opposing electro-osmotic and pressure-driven flow in a narrow 
microchannel to generate controlled bidirectional flow. Widening the channel at both ends 
leads to a recirculating flow pattern, in which polymer microspheres and biological 
particles (yeast, red blood cells, DNA) can be trapped and concentrated, a phenomenon we 
have termed flow-induced electrokinetic trapping (FIET). In fact, the approach depends on 
the relative ratio of applied electric field to pressure; tuning this ratio allows tuning of the 
trap for particles having a particular electrokinetic mobility [9]. Interestingly, FIET also 
allows separation of particles according to size, as particles falling into a narrow mobility 
range but having different sizes will circulate in the flow under a given set of conditions. 
Larger particles will occupy a smaller region of the channel and thus tend to drift towards 
the low-pressure end. In contrast, the net flux of smaller particles will be in the opposite 
Figure 2: Trapping of red blood cells (rat blood diluted with borate buffer). Note 
difference of cell alignment in different flow regions. E = 450 V, P = 4 mbar. 
 
   
 
direction with EOF, allowing these to escape the trapping channel [10]. To date, 
separations of binary mixtures of particles having either different charge or size have been 
demonstrated. In fact, the mechanisms for size-based and charge-based separation are very 
different, so that FIET enables orthogonal microparticle separations in nanoliter volumes.  
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